RSS Feed

Item request has been placed!

Item request cannot be made.

Processing Request

FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

Prostate Cancer in Transgender Women in the Veterans Affairs Health

FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency

FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency

FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency

Pages